Industry News
Long-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of CheckMate -227 in NSCLC First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm New data…
Read More
Data on Genetically Engineered Hypoimmunogenic Human Hepatocytes Demonstrate Proof of Concept in a Metabolic Liver Disease Model Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced new data on its universal hepatocyte program in an oral presentation at the American Society…
Read More
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain. SP-103 is a pharmacologically validated…
Read More
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibody First part of three-part Phase 1/1b trial starts in healthy volunteers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for…
Read More
– Oral presentation of new preclinical data at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – Excerpt from the Press Release: SAN DIEGO, May 19, 2022 /PRNewswire/ — Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative diseases, today announced the presentation of new preclinical data on its…
Read More
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that…
Read More
Study to be Presented at the Global Embolization Oncology Symposium Technologies (GEST) 2022 Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer,…
Read More
The study, published in PLOS ONE, establishes LiquidHALLMARK’s market-leading sensitivity and identifies actionable biomarkers in majority of cancer patients and 70% of lung cancer patients; Mary Jo Mullen joins the Company as SVP, Commercial to oversee US market growth Excerpt from the Press Release: ALO ALTO, Calif.–(BUSINESS WIRE)–Lucence, the precision oncology company pioneering ultrasensitive liquid…
Read More
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with Cancer Findings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
Read More
Excerpt from the Press Release: BOSTON, May 19, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed…
Read More